TR200001412T2 - Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses. - Google Patents

Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses.

Info

Publication number
TR200001412T2
TR200001412T2 TR2000/01412T TR200001412T TR200001412T2 TR 200001412 T2 TR200001412 T2 TR 200001412T2 TR 2000/01412 T TR2000/01412 T TR 2000/01412T TR 200001412 T TR200001412 T TR 200001412T TR 200001412 T2 TR200001412 T2 TR 200001412T2
Authority
TR
Turkey
Prior art keywords
large amount
immediate
drugs
making
providing
Prior art date
Application number
TR2000/01412T
Other languages
English (en)
Inventor
M. Venkatesh Gopadi
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200001412T2 publication Critical patent/TR200001412T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu bulus, yüksek miktarda ilaç içerikli anhidre (E)-alfa-[2-n-butil-1- [(4-karboksifenil)metil] -1H-imidazol-5-yl] metilen-2-tiofenepropionik asitin granülasyonu, üretimi için bir proses, bu bilesigi içeren terkipler ve bu bilesigin anjiyotensin II reseptörlerinin bloke edilmesi ve hipertansiyon, konjestif kalp yetmezligi ve böbrek yetmezliginin tedavisinde kullanimi ile ilgilidir.
TR2000/01412T 1997-11-17 1998-11-17 Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses. TR200001412T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6591897P 1997-11-17 1997-11-17

Publications (1)

Publication Number Publication Date
TR200001412T2 true TR200001412T2 (tr) 2000-09-21

Family

ID=22066009

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01412T TR200001412T2 (tr) 1997-11-17 1998-11-17 Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses.

Country Status (14)

Country Link
EP (1) EP1033974B1 (tr)
JP (1) JP4880118B2 (tr)
KR (1) KR100597922B1 (tr)
CN (1) CN1285739A (tr)
AU (1) AU750611B2 (tr)
BR (1) BR9814877A (tr)
CA (1) CA2310028C (tr)
HU (1) HUP0004407A3 (tr)
IL (1) IL136142A0 (tr)
NO (1) NO329206B1 (tr)
NZ (1) NZ504565A (tr)
PL (1) PL340587A1 (tr)
TR (1) TR200001412T2 (tr)
WO (1) WO1999025321A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912145A (pt) * 1998-07-20 2001-09-25 Smithkline Beecham Corp Formulações bioaperfeiçoadas contendo eprosartan em forma de dosagem sólida oral
MXPA02004413A (es) * 1999-11-02 2002-09-02 Depomed Inc Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago.
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0228878D0 (en) * 2002-06-21 2003-01-15 Unilever Plc Hair conditioning composition
BRPI0406987A (pt) 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
EP2382975A3 (en) * 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2217205B1 (en) * 2007-11-06 2015-03-04 Novartis AG Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
AR072477A1 (es) * 2008-07-11 2010-09-01 Solvay Pharm Bv Formulacion farmaceutica de eprosartan. uso.
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法
TR201007508A1 (tr) * 2010-09-14 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan bileşimler
CN104546779A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 高药物荷载的枸橼酸西地那非片剂及其制备方法
US11510877B2 (en) 2017-10-10 2022-11-29 Capsugel Belgium Nv Gelling multiparticulates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
CA2168647A1 (en) * 1993-08-02 1995-02-09 Barbara A. Sosnowski Monogenous preparations of cytotoxic conjugates
PL188816B1 (pl) * 1996-03-29 2005-04-29 Smithkline Beecham Corp Nowy związek, dwuwodzian monometanosulfonianu kwasu (E)-alfa-[2-n-butylo-1-[(4-karboksyfenylo) metylo]-1H-imidazol-5-ilo] metyleno-2-tiofenopropionowego, sposób jego wytwarzania, kompozycja farmaceutyczna i sposób wytwarzania stałej postaci farmaceutycznej do dawkowania

Also Published As

Publication number Publication date
WO1999025321A1 (en) 1999-05-27
EP1033974B1 (en) 2014-01-22
HUP0004407A1 (hu) 2002-02-28
KR20010032129A (ko) 2001-04-16
CA2310028A1 (en) 1999-05-27
CN1285739A (zh) 2001-02-28
NZ504565A (en) 2002-11-26
CA2310028C (en) 2008-06-10
HUP0004407A3 (en) 2002-03-28
NO329206B1 (no) 2010-09-13
NO20002526L (no) 2000-05-16
AU1588799A (en) 1999-06-07
KR100597922B1 (ko) 2006-07-10
BR9814877A (pt) 2000-10-03
NO20002526D0 (no) 2000-05-16
EP1033974A1 (en) 2000-09-13
EP1033974A4 (en) 2007-05-02
JP4880118B2 (ja) 2012-02-22
IL136142A0 (en) 2001-05-20
JP2001522872A (ja) 2001-11-20
AU750611B2 (en) 2002-07-25
PL340587A1 (en) 2001-02-12

Similar Documents

Publication Publication Date Title
TR200001412T2 (tr) Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses.
TR200202466T2 (tr) Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar.
HUP0103000A2 (hu) Eprosartant tartalmazó, fokozott biológiai hasznosíthatóságú készítmények orális szilárd dózisformában és eljárás az előállításaikra
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
TR199900046T2 (tr) Seçici siklooksijenaz-2 inhibitörleri olarak ikameli piridinler.
KR910007918A (ko) 치환된5-[(테트라졸릴)알케닐]이미다졸
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
TR200103427T2 (tr) Integrinlerin reseptörlerine bağlanmasını engelleyen propanoik asit türevleri.
CA2250395A1 (en) Eprosartan dihydrate and a process for its production and formulation
CY1105851T1 (el) Εξουδετερωσις-φορτιο-συμπλοκου επροσαρταν-αργινυλιου και μεθοδος δια την παραγωγη του και διαμορφωσις
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
TR200101633T2 (tr) Farmasötik bileşim
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
DE60119368D1 (de) Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
ATE342264T1 (de) Indolderivate und deren verwendung als gnrh antagonisten
TR199800521T1 (tr) Seçimli beta3 adrenerjik agonistler.
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
TR200102944T2 (tr) İntegrin reseptör ligandları
ES2182334T3 (es) Monohidrato de eprosartan.
FR2687677B1 (fr) Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
TR200103090T2 (tr) Integrın reseptör antagonistleri